COVID-19 Clinical Trial
Official title:
Effectiveness of Self-proning and Repositioning in Outpatients With COVID-19: a Randomized Controlled Internal Pilot Trial
Verified date | May 2023 |
Source | Unity Health Toronto |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The rapid development of safe and effective COVID-19 treatment is a global health priority. Numerous studies evaluating therapies for this disease are currently underway, but the majority of these are in hospitalized patients with severe illness. Consequently, there is an urgent need to identify therapies that prevent mild COVID-19 cases in the community from becoming more severe. "Proning" or lying face down in bed has been shown to improve breathing and oxygen levels in COVID-19 patients, reducing the need for breathing tubes and ventilators and increasing survival. The current study will investigate whether proning and repositioning (lying on one's side or sitting up) can prevent mild cases of COVID-19 from becoming more severe resulting in fewer hospitalizations and death. A randomized controlled trial will be used to reduce the risk of bias when testing this intervention. Unvaccinated or partially vaccinated adult patients with a positive COVID-19 test willing to participate and well enough to be treated outside the hospital will be randomly assigned to one of two groups: a home-proning intervention group with instructions and daily reminders to prone and reposition during the day and at night, and a standard care group. Our goal is to assess whether home-proning/repositioning leads to fewer hospitalizations and death when compared with standard care. We'll also compare recovery time, use of antibiotics and follow up emergency department visits between these two groups. The current pilot study will assess the feasibility of a larger investigation or "main trial", meaning it will be small scale test of methods and procedures to be used on a larger scale.
Status | Terminated |
Enrollment | 11 |
Est. completion date | February 1, 2023 |
Est. primary completion date | February 1, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Age =18 years 2. Positive SARS-CoV-2 PCR test 3. Presence of two or more of the following criteria: 1. Age>55 years 2. Fever by history or at presentation 3. Cough 4. Dyspnea/shortness of breath 5. Fatigue necessitating daytime bed rest 6. One or more of the following medical conditions: - Hypertension - Diabetes - Cardiovascular disease - Chronic lung disease - Chronic kidney disease - Obesity (BMI=30kg/m2) 7. Tachycardia > 110 bpm 8. Oxygen saturation <94% 9. One or more of the following laboratory abnormalities: - Lymphocytes <1500/microL - ESR > 100 mm/h - CRP > 10 mg/L - D-Dimer > 1000 ng/mL - LDH > 240 U/L 10. Bilateral infiltrates or ground glass opacities on chest x-ray or CT scan 4. Socially and medically fit for discharge 5. Access to a smartphone Exclusion Criteria: 1. Pregnancy >20/40 weeks 2. Body mass index (BMI) >40 kg/m2. 3. Skeletal deformities that interfere with proning 4. Developmental delay or cognitive impairment that would preclude patient cooperation 5. Other contraindications to proning including any of the following: recent abdominal surgery, active vomiting, acute intoxication. 6. Unlikely to adhere to the proning protocol according to the treating physician's judgment 7. Fully vaccinated for COVID-19 |
Country | Name | City | State |
---|---|---|---|
Canada | St. Joseph's Health Centre | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
Unity Health Toronto | Applied Health Research Centre |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Feasibility outcome: successful recruitment | Defined as >=50% of eligible participants agreeing to enrollment | Through study completion, on average one year | |
Other | Feasibility outcome: successful retention of trial participants, | Defined as <10% attrition rate | Up to 28 days | |
Other | Feasibility outcome: adherence to the intervention | Defined as self-proning and repositioning daily for >=75% of days of symptom duration. Adherence will be ascertained through daily survey of study participants. | Up to 28 days | |
Primary | Composite of hospitalization and all cause mortality | The primary outcome is a composite of hospital admission and all-cause mortality. This will be ascertained using telephone follow up and deterministic record linkage performed by the Institute for Clinical Evaluative Sciences (ICES) using their Discharge Abstract Database (DAD). | Up to 28 days post-randomization | |
Secondary | Hospitalization | Up to 28 days post-randomization | ||
Secondary | All cause mortality | Up to 28 days post-randomization | ||
Secondary | Time to functional recovery in days | Defined as: resolution of fever for 48 hours, significant symptom reduction and ability to perform most daily activities or return to work, if applicable, for two consecutive days. | Up to 28 days post-randomization | |
Secondary | Use of antibiotics for respiratory illness | Up to 28 days post-randomization | ||
Secondary | Follow up emergency department assessment without hospital admission | Number of subsequent emergency department visits by study participants that relate to the initial COVID-19 presentation but do not result in hospital admission | Up to 28 days post-randomization |
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|